The US Chose the First Clinical Trial of Coronavirus Medication

After this trial, the issue of vaccine research and development in the US will have many new elements.

Gilead Sciences Inc. said the company has entered the final stage of its coronavirus testing. Accordingly, two studies were conducted at the same time to test the effectiveness and safety of this vaccine in humans, Reuters reported.

US health officials said the first patient was selected for clinical trials of the drug. In early February, media reported that the drug, which is being clinically tested for Covid-19, was once used to prevent a disease in monkeys infected with the Middle East Respiratory Syndrome (MERS).

The US Chose the First Clinical Trial of Coronavirus Medication
The company’s coronavirus vaccine in the US has entered its final phase of clinical trials in humans.

Participants were US citizens repatriated after being isolated in Japan on the Diamond Princess cruise ship. The patient is being treated at the University of Nebraska Medical Center in Omaha, the US National Institutes of Health (NIH) said.

Along with that, starting in March, 1,000 patients in medical centers across Asian countries as well as countries with high cases will be tested for the Remdesivir antiviral drug manufactured by Gilead Company. .

Two doses of Remdesivir will be injected into the patient’s vein in the terminal studies after approval by the US Food and Drug Administration. The main objective of the study was to assess the effectiveness of the drug in patients with normal fevers to see if oxygen balance in the blood could be balanced. The first study will test the drug in about 400 patients infected with corona virus for 5-10 days. While the 2nd study will assess over 600 patients with moderate symptoms.

Gilead said the drug research is being conducted in Hubei province, China (China – Japan Friendship Hospital) and the United States (National Institute of Allergy and Infectious Diseases).


Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button